22
Feb 2026
Hormone-driven immune cells may explain sex differences in chronic pain
Chronic pain lasts longer for women than men, and new research suggests differences in hormone-regulated immune cells, called monocytes, may help explain why.
Cancer Research
Strategic Partnerships
Mercury Pharmaceuticals business strategy is to focus on internal research and development strengths to validate product candidates through proof of concept in cancer patients. We offer access to discovery expertise and product candidates in areas of unmet medical need and distinct commercial value.
Mercury Pharmaceuticals is willing to secure partnerships to enhance our combined ability to advance novel science and accelerate the development of differentiated therapeutics. Our broad intellectual property portfolio and unique research approach enable us to be a productive partner for those seeking to advance meaningful therapeutics in cancer biology, translational oncology, and cancer prevention and control studies.
Mercury Pharmaceuticals has a strategic alliance agreement with Aesica Pharmaceuticals to advance the clinical development for the treatment of ovarian cancer and to collaborate on preclinical studies of MP13920 as a treatment for breast cancer based on positive results from a Phase 2 trial of MP13920 in ovarian cancer patients resistant to paclitaxel (Taxol), the standard of care for this disease.
If interested in learning more, please send us a message.
MERCURY trials
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Cancer
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Neuroscience
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
STAY INFORMED!
22
Feb 2026
New maps of mouse brains reveal patterns of myelin formation
Johns Hopkins scientists say they have used 3D imaging, special microscopes and artificial intelligence (AI) programs to construct new maps of mouse brains showing a precise location of more than 10 million cells called oligodendrocytes.
20
Feb 2026
Indoor air quality plays major role in adult asthma symptoms
For adults with asthma, having fans, air purifiers or other ventilation and exhaust systems - especially in kitchens and bathrooms - is one of the best ways to reduce the risk of flare-ups at home.
20
Feb 2026
Single prenatal exposure to fungicide linked to disease across 20 generations
A single exposure to a toxic fungicide during pregnancy can increase the risk of disease for 20 subsequent generations - with inherited health problems worsening many generations after exposure.
Why Us?
Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.